Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy

Cancer

Volumn 88, Issue 5, 2000, Pages 1091-1098

  Turner, Bruce C ^a   Gumbs, Andrew A ^b   Carbone, Christopher J ^a   Carter, Darryl ^b   Glazer, Peter M ^b   Haffty, Bruce G ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast carcinoma; Conservative therapy; Local relapse; p53

Indexed keywords

PROTEIN P53; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MASTECTOMY, SEGMENTAL; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY DOSAGE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034161651     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000301)88:5<1091::AID-CNCR21>3.0.CO;2-Y     Document Type: Article

References (35)

1. Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, Delena M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305:6-11.
2. Fischer B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. New Engl J Med 1989;320:822-8.
3. Stotter AT, McNeese MD, Ames FC, Oswald MJ, Ellerbroek NA. Predicting the rate and extent of locoregional failure after breast conservation therapy for early breast cancer. Cancer 1989;64:2217-25.
4. Haffty BG, Fischer D, Beinfield M, McKhann C. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 1991;21: 293-8.
5. Haffty BG, Reiss M, Beinfield M, Fischer D, Ward B, McKhann C. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol 1996;14:52-7.
6. Haffty BG, Fischer D, Rose M, McKhann C. Prognostic factors for local recurrence in the conservatively treated breast cancer patient: a cautious interpretation of the data. J Clin Oncol 1991;9:997-1003.
7. Schnitt SJ, Connolly JL, Harris JR, Hellman S, Cohen RB. Pathologic predictors of early local recurrence in stage I and II breast cancer treated by primary radiation therapy. Cancer 1984;53:1049-57.
8. Kurtz JM, Spitalier J-M, Amalric R, Brandone H, Ayme Y, Bressac C, et al. Mammary recurrences in women younger than forty. Int J Radiat Oncol Biol Phys 1988;15:271-6.
9. Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D, et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol 1990;8:591-8.
10. Haffty BG, Brown F, Carter D, Flynn S. Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. Int J Radiat Oncol Biol Phys 1996;35: 751-7.
11. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, et al. Insulin growth factor-1 receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997;57:3079-83.
12. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
13. Volgelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:5236.
14. Lowe SW, Ruley HE, Jacks T, Houseman DE. p-53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
15. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
16. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-52.
17. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J. p53 mutations in breast cancer. Cancer Res 1992;52:5291-8.
18. Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Lijeia DS, Cappa AP. Mutations in the p53 gene in primary human breast cancers. Cancer Res 1991;51:6194-8.
19. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
20. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmber L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1:1029-34.
21. Kovach IS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci U S A 1996;93:1093-6.
22. Aas T, Borreson AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-4.
23. Clahsen PC, van de Velde CJH, Duval C, Pallud C, Mandar AM, Delabelle-Deroide A, et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998;16:470-7.
24. Isola J, Visakorpi T, Holli K. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-14.
25. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappeletti V, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993;85:965-70.
26. Thor AD, Moore DH II, Edgerton SM, Kanasaki ES, Reihaus Z, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
27. Bristow RG, Jang A, Peacock J, Chung S, Benchimol S, Hill RD. Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras. Oncogene 1994;9:1527-36.
28. Haffty BG, Carter D, Flynn SG, Fischer DB, Brash DE, Simons J, et al. Local recurrence versus new primary: clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. Int J Radiat Oncol Biol Phys 1993;27: 575-83.
29. King WJ, DeSombre ER, Jensen EV, Greene GC. Comparison of immunocytochemical and steriod-binding assays for estrogen receptor in human breast tumors. Cancer Res 1985; 45:293-6.
30. Barnes DM, Hanby AM, Gillett CE, Mohammed S, Hodgsen S, Bobrow CG, et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992;340:259-63.
31. Maher MG, Sapi E, Turner BC, Gumbs A, Perrotta PL, Carter D, et al. Prognostic significance of CSF-1R in breast cancer: local recurrence and distant relapse. Clin Cancer Res 1998; 4:1851-6.
32. Turner BC, Harrold E, Gumbs AA, Matloff E, Ward BE, Thomas A, et al. Elevated frequency of germline BRCA1/BRCA2 gene mutations in locally recurrent breast cancer patients following lumpectomy and radiation therapy: implications for breast conserving management in affected patients. Int J Radiat Oncol Biol Phys 1998;42:179.
33. Noguchi S, Koyama H, Kasugai T, Tsukama H, Tsugi N, Tsuala H, et al. A case-control study on risk factors for local recurrence or distant metastases in breast cancer patients treated with breast-conserving surgery. Oncology 1997;54: 468-74.
34. Zellars M, Clark RC, Allred GM, Craig D, Elledge RM. Prognostic value of p53 for local failure in breast cancer patients treated with mastectomy or breast conserving therapy. Int J Radiat Oncol Biol Phys 1998;42:254.
35. Overgaard J, Sorensen SB, Stausbol-Gron B, Hoyer M, Aisner J. TP53 mutation is an independent prognostic marker for poor outcome of radiotherapy in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1998;42: 146.